<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361645</url>
  </required_header>
  <id_info>
    <org_study_id>Vitreo001</org_study_id>
    <nct_id>NCT02361645</nct_id>
  </id_info>
  <brief_title>NSAIDs and PGE2 Levels in Vitrectomy Patients</brief_title>
  <official_title>Vitreous Nonsteroidal Antiinflammatory Drus Concentrations And Prostaglandin E2 Levels in Vitrectomy Patients Treated With Indomethacin 0.5%, Bromfenac 0.09%, and Nepafenac 0.1%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess vitreous concentrations of nonsteroidal
      antiinflammatory drugs (NSAIDs) and prostaglandin E2 in patients treated with NSAIDs before
      vitrectomy.

      A total of 0.5 to 1 mL undiluted vitreous was removed from the midvitreous cavity at the
      beginning of the surgery before infusion with balanced salt solution. Samples were
      immediately frozen and stored at -40°C until analysis. Samples were evaluated in a masked
      fashion. Vitreous concentrations of the study drugs were quantified using a reverse-phase
      liquid chromatography mass spectroscopy system. The minimum quantification limit for
      ketorolac, bromfenac, nepafenac, and amfenac was 0.8 ng/mL. Prostaglandin E2 concentrations
      were determined using a commercially available competitive enzyme immunoassay kit (R &amp; D
      Systems, Minneapolis, MN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostaglandin E2 levels in the vitreous (pg/mL)</measure>
    <time_frame>7 days after NSAID TID administration, following vitrectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NSAIDs concentration (ng/mL) into the vitreous</measure>
    <time_frame>7 days after NSAID TID administration, following vitrectomy</time_frame>
    <description>Vitreous concentrations of the study drugs were quantified using a reverse phase high performance liquid chromatography mass spectroscopy system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 days after NSAID TID administration, following vitrectomy</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Vitreous Inflammation</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No NSAIDs were administered prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac eyedrops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac 0.5% eyedrops were administered prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin eyedrops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin 0.5% eyedrops were administered prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nepafenac eyedrops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac 0.1% eyedrops were administered prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bromfenac eyedrops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromfenac 0.09% eyedrops were administered prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac 0.5% eyedrops</intervention_name>
    <arm_group_label>Ketorolac eyedrops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin 0.5% eyedrops</intervention_name>
    <arm_group_label>Indomethacin eyedrops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac 0.09% eyedrops</intervention_name>
    <arm_group_label>Bromfenac eyedrops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac 0.1% eyedrops</intervention_name>
    <arm_group_label>Nepafenac eyedrops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with pucker scheduled for vitrectomy

        Exclusion Criteria:

          -  diabetes

          -  active inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Andrea Russo</investigator_full_name>
    <investigator_title>PhD Candidate</investigator_title>
  </responsible_party>
  <keyword>nonsteroidal antiinflammatory drugs</keyword>
  <keyword>prostaglandin E2</keyword>
  <keyword>vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

